Huang Wendi, Huang Juan, Huang Nanqu, Luo Yong
Department of Neurology, Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi, China.
Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Lab of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, China.
Front Cell Dev Biol. 2023 Nov 8;11:1280257. doi: 10.3389/fcell.2023.1280257. eCollection 2023.
Triggering receptor expressed on myeloid cells 2 (TREM2), a pattern recognition receptor abundantly expressed on microglia, has been identified as one of the risk factors for Alzheimer's disease (AD). Several studies have already demonstrated the relationship between TREM2 and Tau. TREM2 mutations and altered expression play an important role in Tau phosphorylation. Furthermore, the level of Tau phosphorylation is correlated with soluble TREM2 (sTREM2). However, in different stages of AD, TREM2 seems to have varying effects on Tau pathology. The explicit interaction between TREM2 and Tau, as well as how they affect AD pathology, remains unclear, and there is much evidence to the contrary that requires rational interpretation. Reviewing the dual roles of TREM2 in AD will help identify a more appropriate development strategy for targeting TREM2 to treat AD. Therefore, this review focuses on the interplay between Tau and TREM2 in relation to AD.
髓系细胞触发受体2（TREM2）是一种在小胶质细胞上大量表达的模式识别受体，已被确定为阿尔茨海默病（AD）的危险因素之一。多项研究已经证实了TREM2与Tau之间的关系。TREM2突变和表达改变在Tau磷酸化中起重要作用。此外，Tau磷酸化水平与可溶性TREM2（sTREM2）相关。然而，在AD的不同阶段，TREM2似乎对Tau病理有不同的影响。TREM2与Tau之间的明确相互作用以及它们如何影响AD病理仍不清楚，并且有许多相反的证据需要合理解释。回顾TREM2在AD中的双重作用将有助于确定更合适的靶向TREM2治疗AD的开发策略。因此，本综述重点关注与AD相关的Tau和TREM2之间的相互作用。
